March 31, 2015 – Qu Biologics Inc.
Vancouver, British Columbia – March 31, 2015 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,980,279 relating to the use of immunotherapies derived from components of E. coli to treat Crohn’s disease.
The allowed claims of the patent, which issued on March 17, 2015, cover the use of E. coli components as SSIs to stimulate an immune response to treat Crohn’s disease. This latest patent builds on Qu Biologics’ patent portfolio covering SSI treatment of a range of inflammatory disorders and cancers.
Dr. Hal Gunn, Chief Executive Officer of Qu Biologics commented, “We are very pleased to have been granted this important U.S. patent that covers our novel Crohn’s treatment in clinical use in our randomized, placebo-controlled clinical trial.” Dr. Gunn added, “Our SSIs aim to address the underlying immunological causes of many chronic inflammatory diseases, representing a novel treatment approach that restores the body’s own immune response. We will continue to further strengthen our patent position as we advance our clinical trials in inflammatory bowel disease.”
Qu Biologics’ Site Specific Immunomodulators (SSIs) are derived from components of bacteria and are designed to stimulate the body’s immune system to treat cancer and other immune-related diseases, such as Crohn’s disease and ulcerative colitis. Qu Biologics has developed multiple SSIs, each of which targets a specific organ/tissue.
About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body’s normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many illnesses, including cancer and other immune-related diseases. The company is currently recruiting participants for a clinical trial in Crohn’s disease and a Phase 2a open-label clinical trial in recurrent non-small cell lung cancer to study SSI treatment. A clinical trial in ulcerative colitis has received Health Canada approval and will begin in Q2 2015.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.